GeoVax Labs (GOVX) 10-K 26 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 22, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		278,043,476
Entity Public Float			$ 6,529,024
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
ASSETS
Cash and cash equivalents	$ 259,701	$ 312,727
Grant funds and other receivables	121,814	59,758
Prepaid expenses and other current assets	238,189	75,589
Total current assets	619,704	448,074
Property and equipment, net (Note 3)	11,350	31,151
Deposits	11,010	11,010
Total assets	642,064	490,235
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Accounts payable	125,859	77,581
Accrued expenses (Note 4)	1,238,552	733,711
Current portion of notes payable (Note 5)	260,420
Total current liabilities	1,624,831	811,292
Note payable, net of current portion (Note 5)	39,580
Total liabilities	1,664,411	811,292
Commitments (Note 6)
Stockholders’ equity (deficiency):
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 218,903,476 and 106,736,810 at December 31, 2018 and 2017, respectively	218,903	106,737
Additional paid-in capital	37,264,301	35,589,911
Accumulated deficit	(40,476,884)	(37,916,790)
Total stockholders’ equity (deficiency)	(1,022,347)	(321,057)
Total liabilities and stockholders’ equity (deficiency)	642,064	490,235
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	705,238	842,990
Series D Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock		980,000
Series E Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 1,190,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	218,903,476	106,736,810
Common stock, shares outstanding (in shares)	218,903,476	106,736,810
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	100	100
Preferred stock, shares outstanding (in shares)	100	100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,150	2,570
Preferred stock, shares outstanding (in shares)	2,150	2,570
Series D Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	0	1,000
Preferred stock, shares outstanding (in shares)	0	1,000
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	1,200	0
Preferred stock, shares outstanding (in shares)	1,200	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Grant and collaboration revenue	$ 963,203	$ 1,075,270	$ 828,918
Operating expenses:
Research and development	1,878,652	2,017,350	1,970,859
General and administrative	1,647,268	1,232,368	2,131,426
Total operating expenses	3,525,920	3,249,718	4,102,285
Loss from operations	(2,562,717)	(2,174,448)	(3,273,367)
Other income (expense):
Interest income	5,213	4,286	1,666
Interest expense	(2,590)
Total other income (expense)	2,623	4,286	1,666
Net loss	$ (2,560,094)	$ (2,170,162)	$ (3,271,701)
Basic and diluted:
Loss per common share (in dollars per share)	$ (0.02)	$ (0.03)	$ (0.08)
Weighted average shares outstanding (in shares)	163,584,755	68,605,817	41,516,514

Statement of StockholderConsoli

Statement of StockholderConsolidated Statements of Stockholders' Equity (Deficiency) - USD ($)	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2015	100	3,000			31,950,813
Balance at Dec. 31, 2015	$ 76,095	$ 983,941			$ 31,951	$ 32,587,543	$ (32,474,927)	$ 1,204,603
Conversion of preferred stock to common stock (in shares)		(132)			1,400,000
Conversion of preferred stock to common stock		$ (43,236)			$ 1,400	41,836
Sale of common stock for cash upon warrant exercise (in shares)					21,884,420
Sale of common stock for cash upon warrant exercise					$ 21,884	1,317,917		1,339,801
Stock-based compensation expense						967,667		967,667
Net loss							(3,271,701)	(3,271,701)
Balance (in shares) at Dec. 31, 2016	100	2,868			55,235,233
Balance at Dec. 31, 2016	$ 76,095	$ 940,705			$ 55,235	34,914,963	(35,746,628)	240,370
Conversion of preferred stock to common stock (in shares)		(298)			19,862,000
Conversion of preferred stock to common stock		$ (97,715)			$ 19,862	77,853
Sale of common stock for cash upon warrant exercise (in shares)					31,639,577
Sale of common stock for cash upon warrant exercise					$ 31,640	539,871		571,511
Stock-based compensation expense						57,224		57,224
Net loss							(2,170,162)	(2,170,162)
Sale of convertible preferred stock for cash			$ 980,000					980,000
Balance (in shares) at Dec. 31, 2017	100	2,570	1,000		106,736,810
Balance at Dec. 31, 2017	$ 76,095	$ 842,990	$ 980,000		$ 106,737	35,589,911	(37,916,790)	(321,057)
Conversion of preferred stock to common stock (in shares)		(420)	(1,000)		94,666,666
Conversion of preferred stock to common stock		$ (137,752)	$ (980,000)		$ 94,666	1,023,086
Stock-based compensation expense						155,304		155,304
Net loss							(2,560,094)	(2,560,094)
Sale of convertible preferred stock for cash				$ 1,190,000				$ 1,190,000
Issuance of common stock for services (in shares)					17,500,000			17,500,000
Issuance of common stock for services					$ 17,500	496,000		$ 513,500
Balance (in shares) at Dec. 31, 2018	100	2,150		1,200	218,903,476
Balance at Dec. 31, 2018	$ 76,095	$ 705,238		$ 1,190,000	$ 218,903	$ 37,264,301	$ (40,476,884)	$ (1,022,347)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (2,560,094)	$ (2,170,162)	$ (3,271,701)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,801	28,027	28,780
Stock-based compensation expense	469,724	57,224	967,667
Changes in assets and liabilities:
Grant funds and other receivables	(62,056)	(31,684)	91,904
Prepaid expenses and other current assets	36,480	(13,314)	(5,626)
Accounts payable and accrued expenses	553,119	441,445	242,857
Total adjustments	1,017,068	481,698	1,325,582
Net cash used in operating activities	(1,543,026)	(1,688,464)	(1,946,119)
Cash flows from investing activities:
Purchase of property and equipment		(4,350)
Net cash used in investing activities		(4,350)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	1,190,000	980,000
Net proceeds from sale of common stock		571,511	1,339,801
Proceeds from issuance of notes payable	300,000
Net cash provided by financing activities	1,490,000	1,551,511	1,339,801
Net decrease in cash and cash equivalents	(53,026)	(141,303)	(606,318)
Cash and cash equivalents at beginning of period	312,727	454,030	1,060,348
Cash and cash equivalents at end of period	$ 259,701	$ 312,727	$ 454,030

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Series C Convertible Preferred Stock [Member]
Convertible preferred stock (in shares)	420	298	132
Conversion of stock, shares issued (in shares)	28,000,000	19,862,000	1,400,000
Series D Convertible Preferred Stock [Member]
Convertible preferred stock (in shares)	1,000
Conversion of stock, shares issued (in shares)	66,666,666

Note 1 - Description of Busines

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We aim to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation. Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 13 third 2019. not may not Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 December 15, 2018, 2016 02 Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 262.9 245.3 93.9 December 31, 2018, 2017 2016, Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018 2018 2014 09 no Grant revenue – We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds. Research collaborations – We are pursuing a strategy of co-developing or licensing our technology for specific vaccine development approaches and/or disease indications. Accordingly, we have entered into multiple collaborative research and development agreements and have received third 2014 09 Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense. Period - to - Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 In May 2017, 2017 09, Scope of Modification Accounting 2017 09” 718, 2017 09 1 2 718 2017 09 January 1, 2018; no In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07 718 December 15, 2018, not 2018 07 Other Recent Accounting Pronouncements In July 2017, 2017 11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” 260, 480, 815, 2017 11 2017 11 January 1, 2019. 2017 11 Except as discussed above, there have been no not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and Equipment Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2018 2017: 2018 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (663,246 ) (643,445 ) Property and equipment, net $ 11,350 $ 31,151 Depreciation and leasehold amortization expense was $19,801, $28,027, $28,780 December 31, 2018, 2017 2016,

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued Expenses Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of December 31, 2018 2017: 2018 2017 Accrued management salaries $ 924,509 $ 532,615 Accrued directors’ fees 295,670 182,620 Other accrued expenses 18,373 18,476 Total accrued expenses $ 1,238,552 $ 733,711

Note 5 - Note Payable

Note 5 - Note Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	5 . Notes Payable On February 28, 2018, five $50,000. 5%, second $10,420 2019, $ 12,500 2020, 2021 2022, $2,080 2023. five 178,571 2018 $2,083. On December 27, 2018, two $250,000. three 10,000,000 February 2019, 12

Note 6 - Commitments

Note 6 - Commitments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments Disclosure [Text Block]	6 . Commitments Lease Agreement We lease approximately 8,400 December 31, 2019, December 31, 2022. December 31, 2018, 2017 2016 $156,939, $151,748, $149,288, $161,266 2019, one Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of December 31, 2018, $625,000 2019.

Note 7 - Preferred Stock

Note 7 - Preferred Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Preferred Stock [Text Block]	7 . Preferred Stock Series B Convertible Preferred Stock Our Series B Convertible Preferred Stock, $1,000 no not December 31, 2018, 100 285,714 $76,095. Series C Convertible Preferred Stock In February 2015, 3,000 $1,000 51,333,331 $2,679,810. $1,695,869 $983,941 The Series C Preferred Stock has rights and privileges as set forth in the pertinent Certificate of Designation of Preferences, Rights and Limitations, including a liquidation preference equal to the stated value per share. The Series C Preferred Stock has no not may, 2016, 132 1,400,000 2017, 298 19,862,000 May 2017, $0.05 $0.015 2018, 420 28,000,000 December 31, 2018, 2,150 143,349,733 $705,238. Series D Convertible Preferred Stock In May 2017, 1,000 $1,000 $980,000. no not 2018, 66,666,666 December 31, 2018, no Series E Convertible Preferred Stock In March 2018, 600 $1,000 $590,000. September 2018, 600 $600,000. no not $0.02544 may, December 31, 2018, 1,200 47,169,812 $1,190,000. In connection with the Series E Preferred Stock issuance in September 2018, 47,169,812 $0.02544 six 3 may,

Note 8 - Common Stock

Note 8 - Common Stock	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Common Stock Common Stock Transactions During 2018, 2017, 2016 94,666,666, 19,862,000 1,400,000 7 During 2017 2016 31,639,577 21,884,420 $571,511, $1,339,801, During 2018, 17,500,000 9 Stock Option Plans In 2006 2006 “2006 2016, 2016 “2016 1,412,300 2006 16,000,000 2016 2016 2006 September 28, 2016, no may 2006 2016 may not 110% ten three Certain information concerning our stock option plans as of December 31, 2018, Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted 7,930,000 0.03 Exercised - - Forfeited or expired (235,000 ) 2.96 Outstanding at December 31, 2018 14,719,275 $ 0.11 9.0 $ -0- Exercisable at December 31, 2018 6,795,277 $ 0.19 8.3 $ -0- Stock Purchase Warrants The following table presents a summary of stock purchase warrant activity during the year ended December 31, 2018: Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 - $ - Issued 57,348,383 0.03 Exercised - - Forfeited or expired - - Outstanding and exercisable at December 31, 2018 57,348,383 $ 0.03 Common Stock Reserved A summary of common stock reserved for future issuance as of December 31, 2018 Stock Option Plans 17,412,300 Stock Purchase Warrants 57,348,383 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 143,349,733 Series E Convertible Preferred Stock 47,169,812 Total 265,565,942

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Stock-Based Compensation Stock Option Plans We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows: 2018 2017 2016 Weighted average risk-free interest rates 2.79 % 2.40 % 2.26 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected life of option (in years) 7.0 7.0 7.0 Expected volatility 71.34 % 89.73 % 88.72 % Stock-based compensation expense related to our stock option plans was $155,304, $57,224, $54,805 December 31, 2018, 2017 2016, three December 31, 2018, 2018 2017 2016 General and administrative expense $ 113,306 $ 31,271 $ 31,191 Research and development expense 41,998 25,953 23,614 Total stock option expense $ 155,304 $ 57,224 $ 54,805 As of December 31, 2018, $211,234 2.2 Additional information concerning our stock options for the years ended December 31, 2018, 2017 2016 2018 2017 2016 Weighted average fair value of options granted $ 0.02 $ 0.04 $ 0.05 Intrinsic value of options exercised - - - Total fair value of options vested 153,838 58,337 54,757 Other Non-E mp loyee Stock-Based C ompensation During 2018, 17,500,000 $513,500, $314,419 2018. $199,081 December 31, 2018 2019 2016, $912,862

Note 10 - Retirement Plan

Note 10 - Retirement Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	10 . Retirement Plan We participate in a multi-employer defined contribution retirement plan (the “401k third 401k December 31, 2018, 2017 2016 401k $23,354, $29,265, $33,871,

Note 11 - Income Taxes

Note 11 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11 . Income Taxes At December 31, 2018, $72.5 2019 2038. $1,064,000 2022 2038 No 382 may may On December 22, 2017, not 35% 21%. December 31, 2017, 21%. $10.1 Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at December 31, 2018 2017: 2018 2017 Deferred tax assets: Net operating loss carryforward $ 16,681,908 $ 16,273,259 Research and development tax credit carryforward 1,063,877 949,340 Stock-based compensation expense 1,808,509 1,709,867 Accrued salaries and directors’ fees 317,246 185,961 Depreciation 8,414 5,532 Total deferred tax assets 19,879,954 19,123,959 Deferred tax liabilities - - Net deferred tax assets 19,879,954 19,123,959 Valuation allowance (19,879,954 ) (19,123,959 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0- We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows: 2018 2017 2016 U.S. federal statutory rate applied to pretax loss $ (537,620 ) $ (737,855 ) $ (1,112,378 ) Permanent differences 549 436 2,012 Research and development credits (53,884 ) (57,109 ) (59,087 ) Impact of Tax Act - 10,086,795 - Change in valuation allowance 590,955 (9,292,267 ) 1,169,453 Reported income tax expense $ -0- $ -0- $ -0-

Note 12 - Grants and Collaborat

Note 12 - Grants and Collaboration Revenue	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Government Grants and Contracts [Text Block]	12 . Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During 2018, 2017, 2016, $934,575, $980,270, $828,918, December 31, 2018, $2,589,247 2019 2020. During 2018, 2017, 2016, $28,628, $95,000, 0 third

Note 13 - Subsequent Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	13 . Subsequent Events Conversions of Preferred Stock to Common Stock During January February 2019, 587 39,140,000 March 2019, 180 20,000,000 Exchange of Series C and Series E Preferred Stock for Series F Preferred Stock On February 18, 2019, 2,763 $1,000 no not $0.015 90% may, no Issuance of Series G Preferred Stock On February 25, 2019, 1,000 $1.0 three first February 26, 2019, 500 $250,000 5 $250,000. 50 60 first may $250,000 second 110 to120 first may $250,000 third Each share of Series G Preferred Stock is entitled to a liquidation preference equal to its stated value, has no not $0.015 90% may, At the first 16,666,666 $0.015 six five first may, second third may 33,333,332

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	GEOVAX LABS, INC. SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS For t he Years Ended December 31, 2018, 2017 2016 Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2018 $ 19,123,959 $ 755,995 $ -0- $ -0- $ 19,879,954 Year ended December 31, 2017 28,331,759 (9,207,800 ) -0- -0- 19,123,959 Year ended December 31, 2016 27,131,034 1,200,725 -0- -0- 28,331,759

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 13 third 2019. not may not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments and Concentration of Credit Risk Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from three five In February 2016, No. 2016 02, Leases 2016 02 2016 02 December 15, 2018, 2016 02
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not
Accrued Liabilities [Policy Text Block]	Accrued Expenses As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not third
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 262.9 245.3 93.9 December 31, 2018, 2017 2016,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09 606. five 2014 09 January 1, 2018 2018 2014 09 no Grant revenue – We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds. Research collaborations – We are pursuing a strategy of co-developing or licensing our technology for specific vaccine development approaches and/or disease indications. Accordingly, we have entered into multiple collaborative research and development agreements and have received third 2014 09
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to third
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Costs Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.
Reclassification, Policy [Policy Text Block]	Period - to - Period Comparisons Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument’s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 9 In May 2017, 2017 09, Scope of Modification Accounting 2017 09” 718, 2017 09 1 2 718 2017 09 January 1, 2018; no In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07 718 December 15, 2018, not 2018 07
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recent Accounting Pronouncements In July 2017, 2017 11, (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11” 260, 480, 815, 2017 11 2017 11 January 1, 2019. 2017 11 Except as discussed above, there have been no not

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	2018 2017 Laboratory equipment $ 530,306 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 674,596 674,596 Accumulated depreciation and amortization (663,246 ) (643,445 ) Property and equipment, net $ 11,350 $ 31,151

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2018 2017 Accrued management salaries $ 924,509 $ 532,615 Accrued directors’ fees 295,670 182,620 Other accrued expenses 18,373 18,476 Total accrued expenses $ 1,238,552 $ 733,711

Note 8 - Common Stock (Tables)

Note 8 - Common Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (yrs) Aggregate Intrinsic Value Outstanding at December 31, 2017 7,024,275 $ 0.29 Granted 7,930,000 0.03 Exercised - - Forfeited or expired (235,000 ) 2.96 Outstanding at December 31, 2018 14,719,275 $ 0.11 9.0 $ -0- Exercisable at December 31, 2018 6,795,277 $ 0.19 8.3 $ -0-
Schedule of Warrant Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Outstanding at December 31, 2017 - $ - Issued 57,348,383 0.03 Exercised - - Forfeited or expired - - Outstanding and exercisable at December 31, 2018 57,348,383 $ 0.03
Schedule of Stock by Class [Table Text Block]	Stock Option Plans 17,412,300 Stock Purchase Warrants 57,348,383 Series B Convertible Preferred Stock 285,714 Series C Convertible Preferred Stock 143,349,733 Series E Convertible Preferred Stock 47,169,812 Total 265,565,942

Note 9 - Stock-based Compensa_2

Note 9 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2017 2016 Weighted average risk-free interest rates 2.79 % 2.40 % 2.26 % Expected dividend yield 0.0 % 0.0 % 0.0 % Expected life of option (in years) 7.0 7.0 7.0 Expected volatility 71.34 % 89.73 % 88.72 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2018 2017 2016 General and administrative expense $ 113,306 $ 31,271 $ 31,191 Research and development expense 41,998 25,953 23,614 Total stock option expense $ 155,304 $ 57,224 $ 54,805
Share-based Compensation, Stock Options, Activity [Table Text Block]	2018 2017 2016 Weighted average fair value of options granted $ 0.02 $ 0.04 $ 0.05 Intrinsic value of options exercised - - - Total fair value of options vested 153,838 58,337 54,757

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2018 2017 Deferred tax assets: Net operating loss carryforward $ 16,681,908 $ 16,273,259 Research and development tax credit carryforward 1,063,877 949,340 Stock-based compensation expense 1,808,509 1,709,867 Accrued salaries and directors’ fees 317,246 185,961 Depreciation 8,414 5,532 Total deferred tax assets 19,879,954 19,123,959 Deferred tax liabilities - - Net deferred tax assets 19,879,954 19,123,959 Valuation allowance (19,879,954 ) (19,123,959 ) Net deferred tax asset after reduction for valuation allowance $ -0- $ -0-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 2016 U.S. federal statutory rate applied to pretax loss $ (537,620 ) $ (737,855 ) $ (1,112,378 ) Permanent differences 549 436 2,012 Research and development credits (53,884 ) (57,109 ) (59,087 ) Impact of Tax Act - 10,086,795 - Change in valuation allowance 590,955 (9,292,267 ) 1,169,453 Reported income tax expense $ -0- $ -0- $ -0-

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Summary of Valuation Allowance [Table Text Block]	Additions (Reductions) Description Balance at Beginning Of Period Charged to Costs and Expenses Charged to Other Accounts Deductions Balance at End Of Period Reserve Deducted in the Balance Sheet From the Asset to Which it Applies: Allowance for Deferred Tax Assets Year ended December 31, 2018 $ 19,123,959 $ 755,995 $ -0- $ -0- $ 19,879,954 Year ended December 31, 2017 28,331,759 (9,207,800 ) -0- -0- 19,123,959 Year ended December 31, 2016 27,131,034 1,200,725 -0- -0- 28,331,759

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - shares shares in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	262.9	245.3	93.9
Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life	5 years

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 19,801	$ 28,027	$ 28,780

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 674,596	$ 674,596
Accumulated depreciation and amortization	(663,246)	(643,445)
Property and equipment, net	11,350	31,151
Laboratory Equipment [Member]
Property and equipment, gross	530,306	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 4 - Accrued Expenses - Sch

Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued management salaries	$ 924,509	$ 532,615
Accrued directors’ fees	295,670	182,620
Other accrued expenses	18,373	18,476
Total accrued expenses	$ 1,238,552	$ 733,711

Note 5 - Note Payable (Details

Note 5 - Note Payable (Details Textual) - USD ($)	Feb. 28, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 27, 2018
Proceeds from Notes Payable, Total		$ 300,000
Interest Expense, Total		2,590
Term Notes [Member]
Debt Instrument, Face Amount					$ 250,000
Common Stock Purchase Warrants [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	178,571
Warrants issued to two current investors [Member]
Warrants and Rights Outstanding, Term					3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					10,000,000
Senior Notes [Member]
Debt Instrument, Term	5 years
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months	$ 10,420
Long-term Debt, Maturities, Repayments of Principal in Year Two	12,500
Long-term Debt, Maturities, Repayments of Principal after Year Five	2,080
Interest Expense, Total		$ 2,083
Long-term Debt, Maturities, Repayments of Principal in Year Three	12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five	$ 12,500

Note 6 - Commitments (Details T

Note 6 - Commitments (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)ft²	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Area of Real Estate Property | ft²	8,400
Operating Leases, Rent Expense, Total	$ 156,939	$ 151,748	$ 149,288
Operating Leases, Future Minimum Payments, Due in Two Years	161,266
Unrecorded Unconditional Purchase Obligation, Total	$ 625,000

Note 7 - Preferred Stock (Detai

Note 7 - Preferred Stock (Details Textual) - USD ($)	1 Months Ended				12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018	May 31, 2017	Feb. 28, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 05, 2018
Preferred Stock, Par or Stated Value Per Share					$ 0.01	$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.03
Conversion from Series C Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted					420	298	132
Conversion of Stock, Shares Issued					28,000,000	19,862,000	1,400,000
Warrants Issued in Connection with Series C Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				51,333,331
Adjustments to Additional Paid in Capital, Warrant Issued				$ 1,695,869
Series G Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								47,169,812
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.02544
Warrants and Rights Outstanding, Term								3 years
Series A Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share					$ 1,000
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share					$ 1,000	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance					100	100
Convertible Preferred Stock, Total Conversion Shares					285,714
Preferred Stock, Value, Issued, Ending Balance					$ 76,095	$ 76,095
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 1,000	$ 1,000	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance					2,150	2,570
Convertible Preferred Stock, Total Conversion Shares					143,349,733
Preferred Stock, Value, Issued, Ending Balance					$ 705,238	$ 842,990
Stock Issued During Period, Shares, New Issues				3,000
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total				$ 2,679,810
Stock Issued During Period, Value, New Issues				$ 983,941
Conversion of Stock, Shares Converted					420	298	132
Conversion of Stock, Shares Issued					28,000,000	19,862,000	1,400,000
Convertible Preferred Stock, Conversion Price Per Share						$ 0.05
Convertible Preferred Stock, Conversion Price1						0.015
Series D Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share			$ 1,000		$ 1,000	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance					0	1,000
Preferred Stock, Value, Issued, Ending Balance						$ 980,000
Stock Issued During Period, Shares, New Issues			1,000
Conversion of Stock, Shares Converted					1,000
Conversion of Stock, Shares Issued					66,666,666
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost			$ 980,000
Series E Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share		$ 1,000			$ 1,000	$ 1,000
Preferred Stock, Shares Outstanding, Ending Balance					1,200	0
Convertible Preferred Stock, Total Conversion Shares					47,169,812
Preferred Stock, Value, Issued, Ending Balance					$ 1,190,000
Stock Issued During Period, Shares, New Issues	600
Conversion of Stock, Shares Converted		600
Convertible Preferred Stock, Conversion Price1					$ 0.02544
Proceeds From Issuance Of Convertible Preferred Stock, Net of Issuance Cost	$ 600,000	$ 590,000

Note 8 - Common Stock (Details

Note 8 - Common Stock (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock Issued During Period, Shares, Issued for Services	17,500,000
Common Stock, Capital Shares Reserved for Future Issuance	265,565,942
2006 Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,412,300
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
2006 Equity Incentive Plan [Member] | Incentive Stock Options (ISO's) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent	110.00%
Equity Incentive Plan 2016 [Member]
Common Stock, Capital Shares Reserved for Future Issuance	16,000,000
Expense Associated with Warrant Modifications [Member]
Stock Issued During Period, Shares, Warrants Exercised		31,639,577	21,884,420
Proceeds from Warrant Exercises		$ 571,511	$ 1,339,801
Conversion from Series C and Series D Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued	94,666,666	19,862,000	1,400,000

Note 8 - Common Stock - Activit

Note 8 - Common Stock - Activity of Stock Option Plan (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)$ / sharesshares
Outstanding, options (in shares) | shares	7,024,275
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.29
Granted, options (in shares) | shares	7,930,000
Granted, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.03
Forfeited or expired, options (in shares) | shares	(235,000)
Forfeited or expired, weighted average exercise price, options (in dollars per share) | $ / shares	$ 2.96
Outstanding, options (in shares) | shares	14,719,275
Outstanding, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.11
Outstanding, weighted average exercise price, options (Year)	9 years
Outstanding, weighted average exercise price, options | $	$ 0
Exercisable, options (in shares) | shares	6,795,277
Exercisable at March 31, 2016, weighted average exercise price, options (in dollars per share) | $ / shares	$ 0.19
Exercisable at March 31, 2016, weighted average exercise price, options (Year)	8 years 109 days
Exercisable at March 31, 2016, weighted average exercise price, options | $	$ 0

Note 8 - Common Stock - Activ_2

Note 8 - Common Stock - Activity of Stock Purchase Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding, shares (in shares)
Outstanding, weighted average exercise price (in dollars per share)	$ 0.03
Issued (in shares)	57,348,383
Issued (in dollars per share)	$ 0.03
Exercised (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited or expired (in shares)
Forfeited or expired, weighted average exercise price (in dollars per share)
Outstanding, shares (in shares)	57,348,383

Note 8 - Common Stock - Common

Note 8 - Common Stock - Common Stock Reserved for Future Issuance (Details)	Dec. 31, 2018shares
Common Stock, Reserved for Future Issuance (in shares)	265,565,942
Common Stock [Member]
Common Stock, Reserved for Future Issuance (in shares)	17,412,300
Warrant [Member]
Common Stock, Reserved for Future Issuance (in shares)	57,348,383
Series B Convertible Preferred Stock [Member]
Common Stock, Reserved for Future Issuance (in shares)	285,714
Series C Convertible Preferred Stock [Member]
Common Stock, Reserved for Future Issuance (in shares)	143,349,733
Series E Convertible Preferred Stock [Member]
Common Stock, Reserved for Future Issuance (in shares)	47,169,812

Note 9 - Stock-based Compensa_3

Note 9 - Stock-based Compensation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Stock Issued During Period, Shares, Issued for Services	17,500,000
Stock Issued During Period, Value, Issued for Services	$ 513,500
Stock Issued During Period, Value Expensed During the Period, Issued for Services	314,419
Prepaid Expense, Value of Stock Issued for Services During Period	199,081
General and Administrative Expense, Total	1,647,268	$ 1,232,368	$ 2,131,426
Expense Associated with Warrant Modifications [Member]
General and Administrative Expense, Total			912,862
2006 Equity Incentive Plan [Member]
Allocated Share-based Compensation Expense, Total	155,304	$ 57,224	$ 54,805
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 211,234
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 73 days

Note 9 - Stock-based Compensa_4

Note 9 - Stock-based Compensation - Significant Assumption Used in Fair Value Calculation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted average risk-free interest rates	2.79%	2.40%	2.26%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life of option (Year)	7 years	7 years	7 years
Expected volatility	71.34%	89.73%	88.72%

Note 9 - Stock-based Compensa_5

Note 9 - Stock-based Compensation - Allocation of Stock Option Expense (Details) - Employee Stock Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Allocated stock option expense	$ 155,304	$ 57,224	$ 54,805
General and Administrative Expense [Member]
Allocated stock option expense	113,306	31,271	31,191
Research and Development Expense [Member]
Allocated stock option expense	$ 41,998	$ 25,953	$ 23,614

Note 9 - Stock-based Compensa_6

Note 9 - Stock-based Compensation - Additional Information for Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Weighted average fair value of options granted (in dollars per share)	$ 0.02	$ 0.04	$ 0.05
Intrinsic value of options exercised
Total fair value of options vested	$ 153,838	$ 58,337	$ 54,757

Note 10 - Retirement Plan (Deta

Note 10 - Retirement Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 23,354	$ 29,265	$ 33,871

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Expense (Benefit), Total	$ 0	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	35.00%
Deferred Tax Assets from Remeasurement due to Changes in Enacted Tax Rate	$ (10,100,000)
Deferred Tax Assets from Remeasurement due to Changes in Enacted Tax Rate [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(10,100,000)
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	1,064,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 72,500,000

Note 11 - Income Taxes - Deferr

Note 11 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforward	$ 16,681,908	$ 16,273,259
Research and development tax credit carryforward	1,063,877	949,340
Stock-based compensation expense	1,808,509	1,709,867
Accrued salaries and directors’ fees	317,246	185,961
Depreciation	8,414	5,532
Total deferred tax assets	19,879,954	19,123,959
Deferred tax liabilities
Net deferred tax assets	19,879,954	19,123,959
Valuation allowance	(19,879,954)	(19,123,959)
Net deferred tax asset after reduction for valuation allowance	$ 0	$ 0

Note 11 - Income Taxes - Reconc

Note 11 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
U.S. federal statutory rate applied to pretax loss	$ (537,620)	$ (737,855)	$ (1,112,378)
Permanent differences	549	436	2,012
Research and development credits	(53,884)	(57,109)	(59,087)
Impact of Tax Act		10,086,795
Change in valuation allowance	590,955	(9,292,267)	1,169,453
Reported income tax expense	$ 0	$ 0	$ 0

Note 12 - Grants and Collabor_2

Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue from Contract with Customer, Including Assessed Tax	$ 963,203	$ 1,075,270	$ 828,918
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	934,575	980,270	828,918
Unused Grant Funds	2,589,247
Government Contract [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 28,628	$ 95,000	$ 0

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - USD ($)	May 25, 2019	Feb. 26, 2019	Feb. 25, 2019	Feb. 18, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 28, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Feb. 28, 2015
Preferred Stock, Par or Stated Value Per Share								$ 0.01	$ 0.01
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.03
Series C Convertible Preferred Stock [Member]
Conversion of Stock, Shares Converted								420	298	132
Conversion of Stock, Shares Issued								28,000,000	19,862,000	1,400,000
Preferred Stock, Par or Stated Value Per Share								$ 1,000	$ 1,000		$ 1,000
Convertible Preferred Stock, Conversion Price1									$ 0.015
Preferred Stock, Shares Outstanding, Ending Balance								2,150	2,570
Series E Convertible Preferred Stock [Member]
Conversion of Stock, Shares Converted						600
Preferred Stock, Par or Stated Value Per Share						$ 1,000		$ 1,000	$ 1,000
Convertible Preferred Stock, Conversion Price1								$ 0.02544
Preferred Stock, Shares Outstanding, Ending Balance								1,200	0
Subsequent Event [Member]
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock				2,763
Subsequent Event [Member] | Term Notes [Member]
Debt Instrument, Face Amount, Canceled		$ 250,000
Subsequent Event [Member] | First Closing [Member] | Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			16,666,666
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.015
Warrants and Rights Outstanding, Term			5 years
Subsequent Event [Member] | Second Closing [Member] | Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			33,333,332
Subsequent Event [Member] | Third Closing [Member] | Series I Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			33,333,332
Subsequent Event [Member] | Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized	1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum	$ 1,000,000
Convertible Preferred Stock and Related Warrants Issued		500
Subsequent Event [Member] | Series G Convertible Preferred Stock and Related Warrants [Member] | First Closing [Member]
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum		$ 250,000
Subsequent Event [Member] | Series G Convertible Preferred Stock and Related Warrants [Member] | Second Closing [Member]
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum			$ 250,000
Subsequent Event [Member] | Series G Convertible Preferred Stock and Related Warrants [Member] | Third Closing [Member]
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum			$ 250,000
Subsequent Event [Member] | Series F Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share				$ 1,000
Convertible Preferred Stock, Conversion Price1				$ 0.015
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock				90.00%
Subsequent Event [Member] | Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				0
Subsequent Event [Member] | Series G Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Price1			$ 0.015
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock			90.00%
Subsequent Event [Member] | Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				0
Conversion of Series C Preferred Stock Into Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted							587
Conversion of Stock, Shares Issued							39,140,000
Conversion of Series F Preferred Stock Into Common Stock [Member] | Subsequent Event [Member]
Conversion of Stock, Shares Converted					180
Conversion of Stock, Shares Issued					20,000,000

Schedule II - Valuation and Q_3

Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Balance at Beginning Of Period	$ 19,123,959	$ 28,331,759	$ 27,131,034
Additions Charged to Costs and Expenses	755,995	(9,207,800)	1,200,725
Additions Charged to Other Accounts	0	0	0
Deductions	0	0	0
Balance at End Of Period	$ 19,879,954	$ 19,123,959	$ 28,331,759